Syngen Biotech Co.,Ltd. (TPEX:8279)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
87.50
+0.90 (1.04%)
Jul 30, 2026, 1:09 PM CST
Market Cap2.35B -23.4%
Revenue (ttm)2.05B +1.7%
Net Income226.03M +0.9%
EPS8.33 +1.0%
Shares Out 27.10M
PE Ratio10.40
Forward PEn/a
Dividend5.00 (5.68%)
Ex-Dividend DateJun 25, 2026
Volume9,423
Open87.80
Previous Close86.60
Day's Range86.50 - 87.80
52-Week Range86.30 - 141.00
Beta0.17
Analystsn/a
Price Targetn/a
Earnings DateAug 3, 2026

About Syngen Biotech

Syngen Biotech Co.,Ltd., together with its subsidiaries, engages in the research, development, manufacturing, and sale of microbial pharmaceutical raw materials, biological pesticides, fertilizers and biochemical nutritional products, and preventive medicines in Taiwan and internationally. The company offers dietary supplements; supplement contract manufacturing services in the form of sachets, liquids, tablets, and capsules; and elderly health care, beauty enhancing supplements, probiotics, digestive aids and enzymes, weight loss and nutrition... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1988
Employees 247
Stock Exchange Taipei Exchange
Ticker Symbol 8279
Full Company Profile

Financial Performance

In 2025, Syngen Biotech's revenue was 2.14 billion, an increase of 6.10% compared to the previous year's 2.01 billion. Earnings were 271.59 million, an increase of 13.07%.

Financial Statements